

Reference:	FOI.19020.25
Subject:	Asthma treatments
Date of Request:	4 December 2025

Requested:

1. How many patients have been treated (for any condition) in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
 - Age 6-11
 - Age 12-17
 - Age 18 and above

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:
 - Dupilumab
 - Omalizumab

4. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with:
 - Dupilumab
 - Mepolizumab

5. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year?
 - a. Of these patients, how many have been treated in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of patients that have been treated for any condition, with the listed medications within Secondary Care, during the period 1 August to 30 November 2025.

Medication	Number
Benralizumab	93
Dupilumab	149
Omalizumab	24
Reslizumab	0
Mepolizumab	28
Tezepelumab	129

2. The UHB provides within the table below, the number of patients that received the medications detailed in question 1 within Secondary Care, by the age ranges 0 to 17 and 18 and over, during the period 1 August to 30 November 2025.

Age range	Number
Up to 11	8
12 to 17	13
18 and over	400

Data has been provided for the grouped age range of up to 11 years, as opposed to the requested age group of 6 to 11, due to the low number of cases (5 or less), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

3. The UHB provides within the table below, the number of respiratory patients that have been treated with the listed medications within Secondary Care, during the period 1 August to 30 November 2025.

Medication	Number
Dupilumab	13
Omalizumab	0

4. The UHB does not prescribe the medications listed for the treatment of Chronic Obstructive Pulmonary Disease (COPD) as they are not currently approved by the National Institute for Health and Care Excellence (NICE) for this purpose.
5. The UHB confirms that eleven (11) patients have been diagnosed with both chronic sinusitis and nasal polyps, as recorded on the UHB's Welsh Patient Administration System (WPAS), during the period 1 November 2024 to 31 October 2025.

Please note: The date range provided is the most up to date period available; this is due to a standard clinical coding backlog of up to three (3) months.

- a. The UHB does not prescribe the medications listed for the treatment of sinusitis and nasal polyps as they are not currently approved by the National Institute for Health and Care Excellence (NICE) for the treatment of these conditions. However, Benralizumab has been prescribed to patients that may or may not have also been diagnosed with these conditions, during the period 1 November 2024 to 31 October 2025.